[US Stocks Alert] Kailera Therapeutics soars on October 9th: Phase III enrollment completed, clinical data released, and obesity drug progress

Kailera Therapeutics October 9 Surge Interpretation

Keywords: phase 3 enrollment completion, clinical data, obesity drugs

1. On September 30, the company announced the global KaiNETIC phase 3 project had completed enrollment, covering 3 trials and over 200 research centers. The primary objective is to evaluate weekly injections of the GLP-1/GIP dual receptor agonist lirupatide, with top-line data expected to be released in mid-2028.

2. On October 1, the company presented phase 1 data on lirupatide injection at the EASD 2026 conference. Among 51 trial participants, drug exposure levels after injections in the upper arm or thigh were similar to those after abdominal injections, and no new safety signals were observed. Additionally, the company’s partners submitted four relevant oral presentations.

(Disclaimer: This content is summarized and generated from publicly available information by AI technology. It is for reference only and does not constitute investment advice.)